Exploring the Inflammatory Signature of the anti-cancer Smac-mimetic, Birinapant, and the contribution of this signature to Birinapant anti-Tumour activity

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1101244

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Programmed cell death (PCD) is an essential process for the removal of cancer cells. Defects in PCD are now known to be a causal factor in cancer initiation and chemotherapeutic resistance. Proteins called IAPs protect cancer cells from PCD, however, inhibitors of IAPs have been developed to kill cancer cells in this respect. Indeed, IAP inhibitors can also promote inflammation, which may improve or hamper their efficacy in killing cancer cells, an issue we now wish to explore and exploit.

Funded Activity Details

Start Date: 01-01-2016

End Date: 01-01-2018

Funding Scheme: Project Grants

Funding Amount: $192,322.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Cell Development, Proliferation and Death

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

apoptosis | cancer cell biology | cytokines | inflammation | signalling pathways

Related Links